SC lifts ban on Saridon, two other drugs for now

Image
IANS New Delhi
Last Updated : Sep 17 2018 | 8:00 PM IST

The Supreme court on Monday lifted a ban on the manufacture and sale of Piramal's painkiller Saridon and two other drugs - Piriton and Dart - for now.

These drugs were part of the 328 Fixed Dose Combination (FDC) drugs whose manufacture, distribution and sale was banned by the Ministry of Health and Family Welfare on September 12.

Lifting the ban till the case was disposed, a bench of Justice Rohinton Fali Nariman and Justice Indu Malhotra sought the Centre's response to the pleas by affected pharmaceutical companies against the order to ban FDCs manufactured before 1988.

The bench is hearing cases on the validity of fixed-dose drug licences.

Questioning the ban, the companies had earlier said that the only reason given in the government's notification was that the combinations had "no therapeutic value".

The Centre's decision to ban 328 FDC drugs had brought around 6,000 medicines on the radar, including very commonly used ones.

The list of such drugs includes Piramal's painkiller Saridon, Macleods Pharma's Panderm Plus skin cream, Alkem Laboratories' antibacterial Taxim AZ and combination diabetes drug Gluconorm PG.

The ban order was, however, hailed by the All India Drug Action Network, which said that the government had taken the right decision as "banned drugs were indeed harmful and not prescribed in medicine textbooks".

--IANS

pk/tsb/mr

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 17 2018 | 7:54 PM IST

Next Story